Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)

PHASE3CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

December 14, 2024

Study Completion Date

March 7, 2025

Conditions
Allergic Fungal Rhinosinusitis
Interventions
DRUG

Dupilumab SAR231893

Pharmaceutical form:Injection solution Route of administration: Subcutaneous

DRUG

Placebo

Pharmaceutical form:Injection solution Route of administration: Subcutaneous

Trial Locations (47)

2000

Investigational Site Number : 0320005, Rosario

5500

Investigational Site Number : 0320004, Mendoza

12713

Investigational Site Number : 6820002, Riyadh

22252

Investigational Site Number : 6820001, Riyadh

23507

Eastern Virginia Medical School (EVMS) Medical Group - Otola Site Number : 8400008, Norfolk

29407

National Allergy and Asthma Research, LLC Site Number : 8400002, Charleston

30308

Emory University Hospital Midtown Campus Site Number : 8400009, Atlanta

33613

Asthma Allergy & Immunology Clinical Research Unit Site Number : 8400001, Tampa

34093

Investigational Site Number : 7920001, Istanbul

34865

Investigational Site Number : 7920007, Istanbul

35100

Investigational Site Number : 7920006, Izmir

35340

Investigational Site Number : 7920003, Izmir

37232

Vanderbilt University Medical Center Site Number : 8400013, Nashville

40220

Advanced ENT and Allergy Site Number : 8400004, Louisville

44280

Investigational Site Number : 7920005, Malatya

49100

Investigational Site Number : 3760001, Petah Tikva

70471

South Louisiana Ear, Nose, Throat and Facial Plastic Surgery Site Number : 8400019, Mandeville

76100

Investigational Site Number : 3760002, Rehovot

77030

Ut- Houston Medical School Site Number : 8400010, Houston

78229

USA Clinical Trials Site Number : 8400020, San Antonio

78258

Alamo ENT Associates Site Number : 8400018, San Antonio

100050

Investigational Site Number : 1560005, Beijing

100730

Investigational Site Number : 1560001, Beijing

200030

Investigational Site Number : 1560009, Shanghai

210029

Investigational Site Number : 1560002, Nanjing

266555

Investigational Site Number : 1560011, Qingdao

310003

Investigational Site Number : 1560006, Hangzhou

342005

Investigational Site Number : 3560006, Jodhpur

350005

Investigational Site Number : 1560013, Fuzhou

410013

Investigational Site Number : 1560004, Changsha

610041

Investigational Site Number : 1560003, Chengdu

641028

Investigational Site Number : 3560003, Coimbatore

2591193

Investigational Site Number : 3920010, Isehara

77701-3713

REX Clinical Trials Site Number : 8400017, Beaumont

C1414AIF

Investigational Site Number : 0320003, CABA

C1425BEN

Investigational Site Number : 0320001, CABA

C1121ABE

Investigational Site Number : 0320002, Buenos Aires

V6Z 1Y6

Investigational Site Number : 1240001, Vancouver

Unknown

Investigational Site Number : 1560012, Hefei

030001

Investigational Site Number : 1560008, Taiyuan

110 062.

Investigational Site Number : 3560008, New Delhi

420-0853

Investigational Site Number : 3920006, Shizuoka

113-8431

Investigational Site Number : 3920008, Bunkyo-ku

153-8515

Investigational Site Number : 3920001, Meguro-ku

141-0001

Investigational Site Number : 3920003, Shinagawa-ku

160-8582

Investigational Site Number : 3920009, Shinjuku-ku

01380

Investigational Site Number : 7920004, Adana

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sanofi

INDUSTRY